Mi Jin Oh1, Dong-Yeop Shin1,2,3, Youngil Koh1,2,3, Junshik Hong1,2,3, Inho Kim1, Sung-Soo Yoon1,2,3, Ja Min Byun4,2,3. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 2. Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 3. Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea; jaminbyun@naver.com.
Abstract
BACKGROUND/AIM: For intermediate risk acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally recommended as consolidation after first complete remission (CR1). In real-world, alloSCT might not be readily available, but there is paucity of data on the optimal timing of alloSCT for these patients. PATIENTS AND METHODS: In this pilot study, we compared the outcomes of 13 patients undergoing alloSCT in CR1 with 13 patients undergoing alloSCT after relapse (non-CR1) to examine whether upfront alloSCT yields a better prognosis. RESULTS: There were no differences between the two groups with regards to relapse-free survival (p=0.507) and overall survival (p=0.798). There were more chronic graft-versus-host-disease (GVHD) in the CR1 group compared to the non-CR group (p=0.001), but no difference in acute GVHD. CONCLUSION: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources. Copyright
BACKGROUND/AIM: For intermediate risk acute myeloid leukemiapatients, allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally recommended as consolidation after first complete remission (CR1). In real-world, alloSCT might not be readily available, but there is paucity of data on the optimal timing of alloSCT for these patients. PATIENTS AND METHODS: In this pilot study, we compared the outcomes of 13 patients undergoing alloSCT in CR1 with 13 patients undergoing alloSCT after relapse (non-CR1) to examine whether upfront alloSCT yields a better prognosis. RESULTS: There were no differences between the two groups with regards to relapse-free survival (p=0.507) and overall survival (p=0.798). There were more chronic graft-versus-host-disease (GVHD) in the CR1 group compared to the non-CR group (p=0.001), but no difference in acute GVHD. CONCLUSION: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources. Copyright
Authors: Alan K Burnett; Anthony Goldstone; Robert K Hills; Donald Milligan; Archie Prentice; John Yin; Keith Wheatley; Ann Hunter; Nigel Russell Journal: J Clin Oncol Date: 2013-02-25 Impact factor: 44.544
Authors: Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2016-11-28 Impact factor: 22.113
Authors: M Heuser; Y Ofran; N Boissel; S Brunet Mauri; C Craddock; J Janssen; A Wierzbowska; C Buske Journal: Ann Oncol Date: 2020-03-17 Impact factor: 32.976
Authors: H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas Journal: Transplantation Date: 1974-10 Impact factor: 4.939
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler Journal: JAMA Date: 2009-06-10 Impact factor: 56.272
Authors: Jakob R Passweg; Helen Baldomero; Christian Chabannon; Grzegorz W Basak; Selim Corbacioglu; Rafael Duarte; Harry Dolstra; Arjan C Lankester; Mohamad Mohty; Silvia Montoto; Régis Peffault de Latour; John A Snowden; Jan Styczynski; Ibrahim Yakoub-Agha; Nicolaus Kröger Journal: Bone Marrow Transplant Date: 2020-02-17 Impact factor: 5.483